HOME >> MEDICINE >> NEWS
Bone resorption cells offer drug targets for osteoporosis, rheumatoid arthritis, and more

Washington University pathologist Dr. Steven Teitelbaum describes how he and his colleagues are using their understanding of the role of osteoclasts to develop therapeutic targets for osteoporosis and the bone loss around joints in rheumatoid arthritis. Dr. Teitelbaum was a member of the team that first recognized the cause, then cured osteopetrosis (a fatal disease of the osteoclast cells that absorb bone) in an infant. The infant was cured by a bone marrow transplant that gave her normal bone resorbing cells, but the Teitelbaum group's understanding of how the osteoclasts worked opened the door to development of drugs, such as Fosamax, that inhibit these cells and thus diminish the rate of bone degradation.

To honor this and other ongoing work, Dr. Teitelbaum is the recipient of this year's Rouse Whipple Award, presented by the American Society for Investigative Pathology (ASIP) to a pathologist with an illustrious career in research and continued productivity in the field. His Rouse Whipple Award Lecture on April 3 at the Experimental Biology 2006 meeting in San Francisco is part of ASIP's scientific program.

Bone is continuously broken down (resorbed) by osteoclasts and formed by another type of cells, the osteoblasts. Osteoporosis occurs when the rate of bone resorption surpasses that of bone formation. Dr. Teitelbaum has spent his career trying to understand the precise details of how osteoclasts work, with a recent focus on the discovery, by Dr. Teitelbaum and his colleague F. Patrick Ross, that the bone degrading capacity of osteoclasts depends upon their physical interaction with receptor proteins on the bone surface. Blocking these receptors, known as integrins, also prevents osteoporosis, as demonstrated when mice bred by the researchers to lack genes for the major integrins develop increased bone mass.

Developing drugs that focus on inhibiting the effect of integrins on the osteoclasts has potential advantages, says D
'"/>

Contact: Sarah Goodwin
ebpress@bellsouth.net
770-270-0989
Federation of American Societies for Experimental Biology
3-Apr-2006


Page: 1 2 3

Related medicine news :

1. New cause of tamoxifen resistance in breast cancer cells discovered at Lombardi
2. Study says normal but out-of-control enzyme may be culprit that signals some cells to become cancer
3. New algorithm matches any tumor cells to best possible anti-cancer treatments
4. Aging stem cells in mice may hold answers to diseases of the aged, Stanford study finds
5. Loss of stem cells correlates with premature aging in animal study
6. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells
7. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
8. Stanford researchers track human stem cells transplanted into rat brain
9. Nurse cells make life and death decisions for infection-fighting cells
10. Adult brain cells rediscover their inner child
11. Stem cells provide clues to cancer spread

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... July 10, 2020 , ... Inversion therapy is defined ... out the spine and relieve back pain.” Ergo, the theory is that if the ... while implementing traction for the spine using the head and upper body as the ...
(Date:7/10/2020)... Mich. (PRWEB) , ... July 10, 2020 , ... ... be overwhelming for people with spinal cord disease or injury and social distancing ... COVID-19 pandemic can induce symptoms of anxiety, depression, distress, and PTSD amongst our ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... needs in the field of urology, today announced that Miguel Mercado, M.D., Texas ... Excellence. The designation recognizes that Dr. Mercado has achieved a high level of ...
(Date:7/10/2020)... ... 2020 , ... NeoTract, a wholly owned subsidiary of Teleflex ... announced that Carl Meyer, M.D., The Iowa Clinic in West Des Moines, IA, ... Dr. Meyer has achieved a high level of training and experience with the ...
(Date:7/10/2020)... Fla. (PRWEB) , ... July 10, 2020 , ... ... Expresso® Release 3.0 featuring our Business Partner Vetting (BPV) Portal . ... questionnaires and upload requested documents. No more manually mailing, tracking, and performing other ...
Breaking Medicine News(10 mins):
(Date:7/2/2020)... ... July 02, 2020 , ... ... distributor, is pleased to announce its donation of more than $190,000 in personal ... of Health and Human Services. As extreme medical shortages continue to plague the ...
(Date:7/1/2020)... ... 01, 2020 , ... The final entry deadline for the ... July 28. , The International Business Awards are widely considered to be ... than 4,000 nominations from organizations in more than 70 nations. , All individuals ...
(Date:7/1/2020)... ... July 01, 2020 , ... Stratodesk today announced ... is available on NComputing devices. Thanks to fantastic new growth and stellar adoption ... a new partnership that will make the full Stratodesk NoTouch OS branded image ...
Breaking Medicine Technology:
Cached News: